Naloxone (Narcan): How to Use It and Where to Get It

Recognizing an opioid overdose before calling 911 and administering naloxone takes seconds — and those seconds determine whether the person survives. The classic opioid overdose presents as the triad of unconsciousness, respiratory depression (slow or absent breathing), and pinpoint (miotic) pupils — all caused by opioid binding to mu-opioid receptors throughout the central nervous system and brainstem.

Critical points for overdose recognition:

• Distinguishing overdose from sleep or intoxication: a person who is drunk or heavily intoxicated responds to their name when called loudly; a person who is sleeping wakes up when you shout or shake them; a person in opioid overdose does not respond to painful stimulation — the sternal rub (rubbing knuckles firmly against the breastbone) is the standard layperson test; no response to sternal rub in someone who appears unconscious warrants immediate naloxone administration and 911 call
• Breathing assessment: watch the chest for rise and fall; listen for breath sounds; count breaths for 10 seconds; fewer than 2 breaths in 10 seconds (fewer than 12 per minute) or complete absence of breathing is an overdose emergency; a gurgling or snoring sound — sometimes called the "death rattle" — indicates the airway is partially obstructed by relaxed throat muscles and requires immediate action
• Fentanyl overdose requires faster action and more naloxone: fentanyl and fentanyl analogs are 50–100 times more potent than morphine; they produce faster onset overdose, more complete respiratory depression, and are frequently resistant to reversal with a single naloxone dose; if the person does not respond within 2–3 minutes of naloxone administration, a second dose is needed; fentanyl overdose has become the dominant pattern in opioid fatalities nationwide — assume fentanyl exposure in any suspected opioid overdose and prepare to administer multiple doses

If you are uncertain whether the situation is an overdose — call 911 and administer naloxone anyway. The downside of giving naloxone to someone who was not experiencing an opioid overdose is nil. The downside of not giving it when they were is fatal.

Naloxone administration by a bystander before EMS arrival is the single most important factor in survival from out-of-hospital opioid overdose — the window between respiratory arrest and irreversible brain injury is 4–6 minutes, which is less than average EMS response time in most communities.

Formulation-specific administration notes:

• Narcan 4mg nasal spray (most common lay rescuer formulation): no assembly required; remove from package, hold device with middle and index fingers on either side of nozzle and thumb on bottom of plunger; tilt the person's head back; insert nozzle into one nostril until fingers touch the bottom of their nose; press plunger with thumb firmly — a single press delivers the full 4mg dose; do not test spray prior to administration
• Kloxxado 8mg nasal spray: higher-dose formulation approved for situations where fentanyl exposure is likely; administered identically to Narcan; a single dose delivers 8mg — twice the standard dose — which may reduce the need for a second dose in high-potency opioid overdoses
• EVZIO auto-injector: opens and begins providing voice-guided audio instructions when the cap is removed; follow the voice instructions, which walk the user through injection into the outer thigh through clothing; designed for the most inexperienced possible rescuer in a panic situation
• Intramuscular vials: used by trained first responders and treatment program staff; draw 0.4mg (1mL of 0.4mg/mL solution) into a syringe; inject at 90 degrees into the outer thigh or deltoid muscle; needle penetrates through clothing when needed

After administering naloxone, do not leave the person alone. If they become agitated or aggressive when they wake up (a common response to precipitated withdrawal), calmly explain what happened. Do not allow them to use more opioids to "feel better" — this will precipitate a second overdose when naloxone wears off.

Florida residents can access naloxone through multiple channels — from pharmacies that dispense it without a prescription to free mail-based distribution programs — and the legal environment in Florida has been expanded to protect both people who carry naloxone and those who call 911 to report an overdose.

Cost and insurance coverage:

• Branded Narcan 4mg nasal spray lists at approximately $150 for a 2-pack without insurance; since the OTC approval, retail pricing has come down significantly at some pharmacies
• Generic naloxone nasal spray is now available for approximately $25–$40 for a 2-pack — a major development for cost access; ask your pharmacist specifically for generic naloxone nasal spray
• Insurance coverage: most commercial insurance plans and Medicaid cover naloxone at $0–$10 copay; Florida Medicaid covers naloxone without prior authorization; Verify insurance coverage online to confirm naloxone and MAT benefits before your first appointment

Florida Good Samaritan Law — Florida Statute 893.21:

• Florida's Good Samaritan Law provides immunity from drug-related arrest and prosecution for individuals who call 911 in good faith to report an opioid overdose
• The law protects both the person making the call AND the person experiencing the overdose from prosecution for possession of small amounts of a controlled substance
• The immunity applies at the scene of the overdose; it does not protect against charges unrelated to simple possession (trafficking, weapons charges)
• Fear of arrest is among the most commonly cited reasons bystanders do not call 911 at overdose scenes — knowing your legal protections can save a life

ASAM-certified OUD programs prescribe naloxone to all patients as a standard component of medication-assisted treatment planning — household member education is included in every naloxone prescription protocol.

Naloxone should be accessible to everyone at meaningful risk of witnessing or experiencing an opioid overdose — and the evidence consistently shows that the most common location of a fatal opioid overdose is a private residence, not a street corner, making household naloxone access among the highest-yield harm reduction interventions available.

The following groups have the strongest evidence-based indication for naloxone access:

• Household family members of people with opioid use disorder: family members are frequently the first responders in a home overdose; a 2013 BMJ study found that community naloxone distribution programs — which train and equip family members — are associated with significantly reduced overdose mortality rates at the population level; every family member of someone with OUD should have naloxone and know how to use it
• People receiving prescribed opioids for chronic pain: particularly those on doses above 90 morphine milligram equivalents (MME) per day; those taking opioids in combination with benzodiazepines (a particularly dangerous combination that dramatically increases respiratory depression risk); and those with comorbid conditions that reduce respiratory reserve such as sleep apnea or COPD
• People recently released from incarceration: tolerance drops dramatically and rapidly during incarceration due to enforced abstinence; post-release overdose risk is 10–40 times higher than the general population in the first 2 weeks after release; naloxone at discharge from correctional settings is an evidence-based intervention with mortality benefit
• People in recovery from opioid use disorder: relapse occurs even in people who are highly motivated and engaged in treatment; reduced tolerance following abstinence means a dose that would not have caused overdose during active use can be fatal; having naloxone does not increase the likelihood of relapse — and it dramatically reduces the probability that a relapse becomes fatal
• First responders, neighbors, and community bystanders: lay rescuer naloxone administration before EMS arrival is the most important factor in survival from out-of-hospital opioid overdose; the chain of survival for opioid overdose mirrors cardiac arrest — the first person at the scene determines whether the person lives or dies

The standard of care at ASAM-certified programs includes naloxone prescription at admission for every patient with opioid use disorder, with dedicated naloxone education for household members. Verify insurance coverage to confirm benefits for OUD treatment at a licensed facility.

What happens in the 30–90 minutes after naloxone administration is as clinically important as the administration itself — because naloxone wears off before most opioids do, creating a re-narcotization window that has caused preventable deaths when bystanders assumed their work was done once the person woke up.

The immediate post-naloxone period:

• Precipitated withdrawal is expected: naloxone does not just reverse the overdose — it also rapidly displaces opioids that were producing therapeutic or recreational effects, triggering immediate opioid withdrawal; the person will wake up feeling acutely ill — dysphoric, agitated, nauseated, with muscle cramping, gooseflesh, and intense drug cravings; this is pharmacologically expected and is not a medical emergency; stay calm, reassure the person, explain that they overdosed and that you gave them a medication to reverse it
• Do not leave them alone: naloxone has a half-life of 30–90 minutes; most opioids — and particularly long-acting opioids and fentanyl, which binds mu-receptors with extremely high affinity — remain pharmacologically active for hours; as naloxone clears from the receptor, the opioid can re-bind and reproduce respiratory depression; re-narcotization is documented in the medical literature and is especially common following heroin and fentanyl overdoses; EMS transport to the emergency department for a period of clinical observation is the safest course of action even when the person appears fully and completely recovered
• Managing the agitated post-naloxone patient: a person in precipitated withdrawal is often confused, frightened, and angry; they may not know what happened; they may want to use more opioids to relieve the withdrawal symptoms; do not restrain them or allow them to use more drugs; calmly explain that more opioids could kill them when the naloxone wears off; if they leave before EMS arrives, they are at extremely high risk of re-overdose and death

The overdose moment as a treatment engagement opportunity:

• Emergency department bridge prescribing: research now supports initiating buprenorphine in the emergency department setting for patients presenting with opioid overdose — the "bridge prescribing" model provides a 3–7 day buprenorphine prescription with referral to an outpatient OUD treatment program, dramatically improving treatment engagement rates compared to referral alone
• Same-day treatment engagement: if the person who overdosed is willing to discuss treatment when they arrive in the emergency department or when EMS arrives, ASAM-certified PHP and IOP programs offer same-day clinical assessment with MOUD (buprenorphine) initiation for medically stable individuals.

Learn more about opioid addiction treatment and medication-assisted treatment options in Florida. Verify insurance coverage — most PPO plans cover PHP, IOP, and buprenorphine MAT as essential health benefits.

The claim that naloxone distribution enables drug use is the most persistent and dangerous misconception in the public debate around harm reduction — and it is directly contradicted by the available evidence from multiple large-scale studies, natural experiments, and two decades of peer-reviewed public health research.

What the research shows:

• Naloxone distribution does not increase opioid use: Traci Green and colleagues' research on naloxone distribution programs found no evidence of increased opioid use or injection rates among program participants; a 2013 BMJ study by Walley and colleagues compared counties in Massachusetts with and without naloxone distribution and found a 46–48% lower opioid overdose death rate in counties with naloxone programs — with no corresponding increase in opioid use prevalence; the epidemiological evidence base is unambiguous on this point
• The mechanism of the objection is pharmacologically unfounded: naloxone does not produce euphoria; it does not make drug use more pleasurable; it does not reduce the consequences of opioid use in any way that would be experienced as reward; the idea that someone would use more heroin or fentanyl because naloxone is available requires that the person is deterred from use by fear of death — a deterrence model with essentially no empirical support in the addiction science literature
• What naloxone does: it saves lives; a person who survives an overdose retains the opportunity to enter treatment and achieve recovery; a person who dies from an overdose does not; the public health framing is straightforward — naloxone is what makes treatment possible by keeping people alive until they are ready or able to access care; visit our drug overdose resource page for more on the epidemiology of opioid overdose death in America, or see Florida overdose statistics for state-level fatality and trend data

The recovery community perspective:

• The vast majority of people in long-term recovery from opioid use disorder support naloxone access without restriction; they understand that overdose survival is what allowed them to reach treatment; "naloxone saved my life so I could get sober" is among the most commonly shared stories in OUD recovery communities
• Organizations representing people in recovery — including SMART Recovery, the National Alliance for Medication Assisted Recovery (NAMA), and community recovery advocacy groups — have uniformly supported expanded naloxone access

The clinical position of addiction medicine is unambiguous: naloxone is a life-saving medication that should be prescribed to every patient with opioid use disorder and their household members. Reducing overdose deaths is the foundation of any meaningful addiction treatment system — without survival, recovery is impossible.

ASAM-certified treatment programs in Florida prescribe naloxone to all OUD patients as a standard of care. If you or someone you love is struggling with opioid use disorder, verify insurance coverage for PHP and IOP treatment — most commercial plans cover the full continuum from MAT through outpatient.